Vertex's Journavx (Suzetrigine): The First Non-Opioid Painkiller in Decades — What's Next

Last updated July 24, 2026: This article originally described an “August 30 PDUFA date” for suzetrigine as an upcoming event. That PDUFA date was incorrect — the FDA approved suzetrigine (Journavx) on January 30, 2025 for moderate-to-severe acute pain. The article has been rewritten to reflect the drug’s approved status and current pipeline outlook.

The FDA approved Vertex Pharmaceuticals’ suzetrigine (Journavx) on January 30, 2025 — the first new class of pain medicine approved in more than 20 years. It is the first and only approved non-opioid oral pain signal inhibitor, indicated for adults with moderate-to-severe acute pain.

Why this matters

Acute pain management has been stuck with two options: opioids (effective but addictive and dangerous) and NSAIDs (safe but not strong enough for severe pain). Suzetrigine is a NaV1.8 inhibitor — it blocks a sodium channel found only in peripheral pain neurons, not in the brain or central nervous system.

That selectivity is the key. By targeting only peripheral pain signals, suzetrigine provides opioid-level pain relief without the addiction, respiratory depression, and constipation that make opioids dangerous.

The data behind the approval

The Phase 3 program that supported approval included two acute pain trials:

1. Bunionectomy: 40% reduction in pain vs. 29% on placebo (p < 0.001). Suzetrigine matched hydrocodone bitartrate/acetaminophen (the opioid comparator).
2. Abdominoplasty: 48% reduction in pain vs. 31% on placebo (p < 0.001).

The safety profile was clean: no signs of addiction potential, no respiratory depression, no meaningful CNS side effects. The most common side effects were headache and nausea. The DEA did not schedule suzetrigine as a controlled substance.

The market

The acute pain market is enormous. Over 80 million surgical procedures happen in the US each year, and opioids are still the standard despite the addiction crisis. Journavx is the first new mechanistic class of pain medicine approved in decades.

Peak sales estimates range from $1.5–3 billion for the acute pain indication alone. Vertex is also developing suzetrigine for chronic pain (neuropathic pain), which could double the market.

Vertex’s stock closed at $473.09 on July 24, 2026. The stock is up modestly YTD, driven by Journavx’s launch ramp and the broader pipeline, including the pending Crinetics acquisition.

What we’re watching

1. Launch trajectory: Vertex has no historical commercial pain infrastructure. Early prescription data in 2025–2026 will tell us how fast adoption happens. Analysts model Journavx reaching $1 billion in sales by 2028.
2. Chronic pain expansion: Phase 3 data in painful diabetic peripheral neuropathy is expected in 2027. Vertex is also advancing a pivotal program in lumbosacral radiculopathy. This is the bigger opportunity — chronic pain is a much larger market than acute pain.
3. Competition: The NaV1.8 inhibitor class is now validated. Other companies are developing similar molecules, but Vertex has a multi-year head start.

Journavx is the most significant pain management development in a generation. The next chapter is whether it can expand beyond acute pain into the much larger chronic pain market.